Quickly find freely available drug and population models in our PBPK model repository.
The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.
You can use a suffix operator (*) as the placeholder for end of a term. The query must start with at least one alphanumeric character before the suffix operator. E.g., Rifam* will get you “Rifampicin” and “Rifampin”. For more advanced searching tips click here.
Brand Name(s) include: Viracept
Disease: HIV
Drug Class: Protease Inhibitor
Version: 21
Date Updated: March 2023
|
Absorption Model |
ADAM (Solution) |
| Volume of Distribution Details |
Full PBPK (Method 2) |
|
Route of Elimination |
|
|
Perpetrator DDI |
|
|
Validation |
The refined model was able to recover clinically observed concentration-time profiles of nelfinavir following single and multiple dosing. Six clinical DDI studies where nelfinavir was administered with either ritonavir, rifampicin, rifabutin, efavirenz, and nevirapine were used to verify the PBPK model of nevirapine as a victim. In comparison of predicted vs. observed AUC, 100% of the studies were within 1.5-fold. Nine clinical DDI studies where nevirapine was administered with either alfentanil, midazolam, simvastatin, atorvastatin, rifabutin, or digoxin were used to verify the PBPK model of nevirapine as a perpetrator. In comparison of predicted vs. observed AUC, 100% of the studies were within 2-fold and 78% were within 1.25-fold. |
|
Limitations |
|
Brand Name: Viramune
Disease: HIV
Drug Class: non-nucleoside reverse transcriptase inhibitor
Version: 21
Date Updated: March 2024
|
Absorption Model |
First order |
| Volume of Distribution Details |
Full PBPK (Method 2) |
|
Route of Elimination |
|
|
Perpetrator DDI |
|
|
Validation |
The refined model was able to recover clinically observed concentration-time profiles of nevirapine following single and multiple dosing. Four clinical DDI studies where nevirapine was administered with either fluconazole, rifampin, or itraconazole were used to verify the PBPK model of nevirapine as a victim. In comparison of predicted vs. observed AUC, 100% of the studies were within 1.25-fold. Two clinical DDI studies where nevirapine was administered with either itraconazole or quinidine were used to verify the PBPK model of nevirapine as a perpetrator. In comparison of predicted vs. observed AUC, 100% of the studies were within 1.5-fold. |
|
Limitations |
|
.
|
|< |
< |
1 |